In the current model, we focused on the prevention of gastrointestinal amyloidosis using neutralizing antibodies against inflammatory cytokines TNF-α and IL-1α/β; however, amyloidosis was partially ameliorated in both groups. Here, IL1A is linked to amyloidosis.